Loading…

Development and Binding Mode Assessment of N‑[4-[2-Propyn-1-yl[(6S)‑4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo‑3H‑cyclopenta[g]quinazolin-6-yl]amino]benzoyl]‑l‑γ-glutamyl‑d‑glutamic Acid (BGC 945), a Novel Thymidylate Synthase Inhibitor That Targets Tumor Cells

N-[4-[2-Propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-d-glutamic acid 1 (BGC 945, now known as ONX 0801), is a small molecule thymidylate synthase (TS) inhibitor discovered at the Institute of Cancer Research in London. It is...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 2013-07, Vol.56 (13), p.5446-5455
Main Authors: Tochowicz, Anna, Dalziel, Sean, Eidam, Oliv, O’Connell, Joseph D, Griner, Sarah, Finer-Moore, Janet S, Stroud, Robert M
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a405t-ba70a21b924b3eab6f9ef5ff2973851f1e654a55287cb2319ff5ee0ffb97ed7b3
cites cdi_FETCH-LOGICAL-a405t-ba70a21b924b3eab6f9ef5ff2973851f1e654a55287cb2319ff5ee0ffb97ed7b3
container_end_page 5455
container_issue 13
container_start_page 5446
container_title Journal of medicinal chemistry
container_volume 56
creator Tochowicz, Anna
Dalziel, Sean
Eidam, Oliv
O’Connell, Joseph D
Griner, Sarah
Finer-Moore, Janet S
Stroud, Robert M
description N-[4-[2-Propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-d-glutamic acid 1 (BGC 945, now known as ONX 0801), is a small molecule thymidylate synthase (TS) inhibitor discovered at the Institute of Cancer Research in London. It is licensed by Onyx Pharmaceuticals and is in phase 1 clinical studies. It is a novel antifolate drug resembling TS inhibitors plevitrexed and raltitrexed that combines enzymatic inhibition of thymidylate synthase with α-folate receptor-mediated targeting of tumor cells. Thus, it has potential for efficacy with lower toxicity due to selective intracellular accumulation through α-folate receptor (α-FR) transport. The α-FR, a cell-surface receptor glycoprotein, which is overexpressed mainly in ovarian and lung cancer tumors, has an affinity for 1 similar to that for its natural ligand, folic acid. This study describes a novel synthesis of 1, an X-ray crystal structure of its complex with Escherichia coli TS and 2′-deoxyuridine-5′-monophosphate, and a model for a similar complex with human TS.
doi_str_mv 10.1021/jm400490e
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3880649</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1490716465</sourcerecordid><originalsourceid>FETCH-LOGICAL-a405t-ba70a21b924b3eab6f9ef5ff2973851f1e654a55287cb2319ff5ee0ffb97ed7b3</originalsourceid><addsrcrecordid>eNptks9uEzEQxhcEoqFw4MIR-YKUSDHYXu-_C1IaoK1UClLDKYpW3t3ZrKNdO7W9VbcnXoFn4T14CJ4EtykRSBzG9nh--sYefUHwgpI3lDD6dtNxQnhG4GEwohEjmKeEPwpGhDCGWczCg-CptRtCSEhZ-CQ4YGFCSZRlowcv38MVtHrbgXJIqAodSVVJtUafdAVoZi1Ye1fTNTr_9e37kuMlw1-M3g4KUzy0y3F8MfEFPo2nyTTFDpwRzVAZjRke3x2uhw5cM7QTzLG-1h4OT_xSDqVv7LXFcr267KUSN7qVCsdedSU6qfSqAHWjfebp1sfPH3jd9k50w21W-dilskSzUlZofHQ8RxmPJlMk0Ln2H0OLZuhkNbTCAboYlGuEBXSqGllIp40vC4cWwqzBWbToO381h7a1z4LHtWgtPL_fD4OvHz8s5if47PPx6Xx2hgUnkcOFSIhgtMgYL0IQRVxnUEd1zbIkTCNaU4gjLqKIpUlZsJBmdR0BkLousgSqpAgPg3c73W1fdFCVfhpGtPnWyE6YIddC5v9WlGzytb7KwzQlMc-8wPhewOjLHqzLO2lL_wWhQPc2p94WCY15HHl0skNLo601UO_bUJLf-ijf-8izr_5-1578YxwPvN4BorT5RvdG-TH9R-g3YzzbYA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490716465</pqid></control><display><type>article</type><title>Development and Binding Mode Assessment of N‑[4-[2-Propyn-1-yl[(6S)‑4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo‑3H‑cyclopenta[g]quinazolin-6-yl]amino]benzoyl]‑l‑γ-glutamyl‑d‑glutamic Acid (BGC 945), a Novel Thymidylate Synthase Inhibitor That Targets Tumor Cells</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><creator>Tochowicz, Anna ; Dalziel, Sean ; Eidam, Oliv ; O’Connell, Joseph D ; Griner, Sarah ; Finer-Moore, Janet S ; Stroud, Robert M</creator><creatorcontrib>Tochowicz, Anna ; Dalziel, Sean ; Eidam, Oliv ; O’Connell, Joseph D ; Griner, Sarah ; Finer-Moore, Janet S ; Stroud, Robert M</creatorcontrib><description>N-[4-[2-Propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-d-glutamic acid 1 (BGC 945, now known as ONX 0801), is a small molecule thymidylate synthase (TS) inhibitor discovered at the Institute of Cancer Research in London. It is licensed by Onyx Pharmaceuticals and is in phase 1 clinical studies. It is a novel antifolate drug resembling TS inhibitors plevitrexed and raltitrexed that combines enzymatic inhibition of thymidylate synthase with α-folate receptor-mediated targeting of tumor cells. Thus, it has potential for efficacy with lower toxicity due to selective intracellular accumulation through α-folate receptor (α-FR) transport. The α-FR, a cell-surface receptor glycoprotein, which is overexpressed mainly in ovarian and lung cancer tumors, has an affinity for 1 similar to that for its natural ligand, folic acid. This study describes a novel synthesis of 1, an X-ray crystal structure of its complex with Escherichia coli TS and 2′-deoxyuridine-5′-monophosphate, and a model for a similar complex with human TS.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm400490e</identifier><identifier>PMID: 23710599</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Crystallography, X-Ray ; Drug Design ; Enzyme Inhibitors - chemical synthesis ; Enzyme Inhibitors - metabolism ; Enzyme Inhibitors - pharmacology ; Escherichia coli - enzymology ; Escherichia coli Proteins - antagonists &amp; inhibitors ; Escherichia coli Proteins - chemistry ; Escherichia coli Proteins - metabolism ; Folic Acid Antagonists - chemical synthesis ; Folic Acid Antagonists - metabolism ; Folic Acid Antagonists - pharmacology ; Humans ; Models, Chemical ; Models, Molecular ; Molecular Structure ; Neoplasms - enzymology ; Neoplasms - pathology ; Protein Binding ; Protein Structure, Tertiary ; Quinazolines - chemical synthesis ; Quinazolines - metabolism ; Quinazolines - pharmacology ; Thymidylate Synthase - antagonists &amp; inhibitors ; Thymidylate Synthase - chemistry ; Thymidylate Synthase - metabolism</subject><ispartof>Journal of medicinal chemistry, 2013-07, Vol.56 (13), p.5446-5455</ispartof><rights>Copyright © 2013 American Chemical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a405t-ba70a21b924b3eab6f9ef5ff2973851f1e654a55287cb2319ff5ee0ffb97ed7b3</citedby><cites>FETCH-LOGICAL-a405t-ba70a21b924b3eab6f9ef5ff2973851f1e654a55287cb2319ff5ee0ffb97ed7b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23710599$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tochowicz, Anna</creatorcontrib><creatorcontrib>Dalziel, Sean</creatorcontrib><creatorcontrib>Eidam, Oliv</creatorcontrib><creatorcontrib>O’Connell, Joseph D</creatorcontrib><creatorcontrib>Griner, Sarah</creatorcontrib><creatorcontrib>Finer-Moore, Janet S</creatorcontrib><creatorcontrib>Stroud, Robert M</creatorcontrib><title>Development and Binding Mode Assessment of N‑[4-[2-Propyn-1-yl[(6S)‑4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo‑3H‑cyclopenta[g]quinazolin-6-yl]amino]benzoyl]‑l‑γ-glutamyl‑d‑glutamic Acid (BGC 945), a Novel Thymidylate Synthase Inhibitor That Targets Tumor Cells</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>N-[4-[2-Propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-d-glutamic acid 1 (BGC 945, now known as ONX 0801), is a small molecule thymidylate synthase (TS) inhibitor discovered at the Institute of Cancer Research in London. It is licensed by Onyx Pharmaceuticals and is in phase 1 clinical studies. It is a novel antifolate drug resembling TS inhibitors plevitrexed and raltitrexed that combines enzymatic inhibition of thymidylate synthase with α-folate receptor-mediated targeting of tumor cells. Thus, it has potential for efficacy with lower toxicity due to selective intracellular accumulation through α-folate receptor (α-FR) transport. The α-FR, a cell-surface receptor glycoprotein, which is overexpressed mainly in ovarian and lung cancer tumors, has an affinity for 1 similar to that for its natural ligand, folic acid. This study describes a novel synthesis of 1, an X-ray crystal structure of its complex with Escherichia coli TS and 2′-deoxyuridine-5′-monophosphate, and a model for a similar complex with human TS.</description><subject>Crystallography, X-Ray</subject><subject>Drug Design</subject><subject>Enzyme Inhibitors - chemical synthesis</subject><subject>Enzyme Inhibitors - metabolism</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Escherichia coli - enzymology</subject><subject>Escherichia coli Proteins - antagonists &amp; inhibitors</subject><subject>Escherichia coli Proteins - chemistry</subject><subject>Escherichia coli Proteins - metabolism</subject><subject>Folic Acid Antagonists - chemical synthesis</subject><subject>Folic Acid Antagonists - metabolism</subject><subject>Folic Acid Antagonists - pharmacology</subject><subject>Humans</subject><subject>Models, Chemical</subject><subject>Models, Molecular</subject><subject>Molecular Structure</subject><subject>Neoplasms - enzymology</subject><subject>Neoplasms - pathology</subject><subject>Protein Binding</subject><subject>Protein Structure, Tertiary</subject><subject>Quinazolines - chemical synthesis</subject><subject>Quinazolines - metabolism</subject><subject>Quinazolines - pharmacology</subject><subject>Thymidylate Synthase - antagonists &amp; inhibitors</subject><subject>Thymidylate Synthase - chemistry</subject><subject>Thymidylate Synthase - metabolism</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNptks9uEzEQxhcEoqFw4MIR-YKUSDHYXu-_C1IaoK1UClLDKYpW3t3ZrKNdO7W9VbcnXoFn4T14CJ4EtykRSBzG9nh--sYefUHwgpI3lDD6dtNxQnhG4GEwohEjmKeEPwpGhDCGWczCg-CptRtCSEhZ-CQ4YGFCSZRlowcv38MVtHrbgXJIqAodSVVJtUafdAVoZi1Ye1fTNTr_9e37kuMlw1-M3g4KUzy0y3F8MfEFPo2nyTTFDpwRzVAZjRke3x2uhw5cM7QTzLG-1h4OT_xSDqVv7LXFcr267KUSN7qVCsdedSU6qfSqAHWjfebp1sfPH3jd9k50w21W-dilskSzUlZofHQ8RxmPJlMk0Ln2H0OLZuhkNbTCAboYlGuEBXSqGllIp40vC4cWwqzBWbToO381h7a1z4LHtWgtPL_fD4OvHz8s5if47PPx6Xx2hgUnkcOFSIhgtMgYL0IQRVxnUEd1zbIkTCNaU4gjLqKIpUlZsJBmdR0BkLousgSqpAgPg3c73W1fdFCVfhpGtPnWyE6YIddC5v9WlGzytb7KwzQlMc-8wPhewOjLHqzLO2lL_wWhQPc2p94WCY15HHl0skNLo601UO_bUJLf-ijf-8izr_5-1578YxwPvN4BorT5RvdG-TH9R-g3YzzbYA</recordid><startdate>20130711</startdate><enddate>20130711</enddate><creator>Tochowicz, Anna</creator><creator>Dalziel, Sean</creator><creator>Eidam, Oliv</creator><creator>O’Connell, Joseph D</creator><creator>Griner, Sarah</creator><creator>Finer-Moore, Janet S</creator><creator>Stroud, Robert M</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130711</creationdate><title>Development and Binding Mode Assessment of N‑[4-[2-Propyn-1-yl[(6S)‑4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo‑3H‑cyclopenta[g]quinazolin-6-yl]amino]benzoyl]‑l‑γ-glutamyl‑d‑glutamic Acid (BGC 945), a Novel Thymidylate Synthase Inhibitor That Targets Tumor Cells</title><author>Tochowicz, Anna ; Dalziel, Sean ; Eidam, Oliv ; O’Connell, Joseph D ; Griner, Sarah ; Finer-Moore, Janet S ; Stroud, Robert M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a405t-ba70a21b924b3eab6f9ef5ff2973851f1e654a55287cb2319ff5ee0ffb97ed7b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Crystallography, X-Ray</topic><topic>Drug Design</topic><topic>Enzyme Inhibitors - chemical synthesis</topic><topic>Enzyme Inhibitors - metabolism</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Escherichia coli - enzymology</topic><topic>Escherichia coli Proteins - antagonists &amp; inhibitors</topic><topic>Escherichia coli Proteins - chemistry</topic><topic>Escherichia coli Proteins - metabolism</topic><topic>Folic Acid Antagonists - chemical synthesis</topic><topic>Folic Acid Antagonists - metabolism</topic><topic>Folic Acid Antagonists - pharmacology</topic><topic>Humans</topic><topic>Models, Chemical</topic><topic>Models, Molecular</topic><topic>Molecular Structure</topic><topic>Neoplasms - enzymology</topic><topic>Neoplasms - pathology</topic><topic>Protein Binding</topic><topic>Protein Structure, Tertiary</topic><topic>Quinazolines - chemical synthesis</topic><topic>Quinazolines - metabolism</topic><topic>Quinazolines - pharmacology</topic><topic>Thymidylate Synthase - antagonists &amp; inhibitors</topic><topic>Thymidylate Synthase - chemistry</topic><topic>Thymidylate Synthase - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tochowicz, Anna</creatorcontrib><creatorcontrib>Dalziel, Sean</creatorcontrib><creatorcontrib>Eidam, Oliv</creatorcontrib><creatorcontrib>O’Connell, Joseph D</creatorcontrib><creatorcontrib>Griner, Sarah</creatorcontrib><creatorcontrib>Finer-Moore, Janet S</creatorcontrib><creatorcontrib>Stroud, Robert M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tochowicz, Anna</au><au>Dalziel, Sean</au><au>Eidam, Oliv</au><au>O’Connell, Joseph D</au><au>Griner, Sarah</au><au>Finer-Moore, Janet S</au><au>Stroud, Robert M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development and Binding Mode Assessment of N‑[4-[2-Propyn-1-yl[(6S)‑4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo‑3H‑cyclopenta[g]quinazolin-6-yl]amino]benzoyl]‑l‑γ-glutamyl‑d‑glutamic Acid (BGC 945), a Novel Thymidylate Synthase Inhibitor That Targets Tumor Cells</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2013-07-11</date><risdate>2013</risdate><volume>56</volume><issue>13</issue><spage>5446</spage><epage>5455</epage><pages>5446-5455</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><abstract>N-[4-[2-Propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-d-glutamic acid 1 (BGC 945, now known as ONX 0801), is a small molecule thymidylate synthase (TS) inhibitor discovered at the Institute of Cancer Research in London. It is licensed by Onyx Pharmaceuticals and is in phase 1 clinical studies. It is a novel antifolate drug resembling TS inhibitors plevitrexed and raltitrexed that combines enzymatic inhibition of thymidylate synthase with α-folate receptor-mediated targeting of tumor cells. Thus, it has potential for efficacy with lower toxicity due to selective intracellular accumulation through α-folate receptor (α-FR) transport. The α-FR, a cell-surface receptor glycoprotein, which is overexpressed mainly in ovarian and lung cancer tumors, has an affinity for 1 similar to that for its natural ligand, folic acid. This study describes a novel synthesis of 1, an X-ray crystal structure of its complex with Escherichia coli TS and 2′-deoxyuridine-5′-monophosphate, and a model for a similar complex with human TS.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>23710599</pmid><doi>10.1021/jm400490e</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 2013-07, Vol.56 (13), p.5446-5455
issn 0022-2623
1520-4804
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3880649
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)
subjects Crystallography, X-Ray
Drug Design
Enzyme Inhibitors - chemical synthesis
Enzyme Inhibitors - metabolism
Enzyme Inhibitors - pharmacology
Escherichia coli - enzymology
Escherichia coli Proteins - antagonists & inhibitors
Escherichia coli Proteins - chemistry
Escherichia coli Proteins - metabolism
Folic Acid Antagonists - chemical synthesis
Folic Acid Antagonists - metabolism
Folic Acid Antagonists - pharmacology
Humans
Models, Chemical
Models, Molecular
Molecular Structure
Neoplasms - enzymology
Neoplasms - pathology
Protein Binding
Protein Structure, Tertiary
Quinazolines - chemical synthesis
Quinazolines - metabolism
Quinazolines - pharmacology
Thymidylate Synthase - antagonists & inhibitors
Thymidylate Synthase - chemistry
Thymidylate Synthase - metabolism
title Development and Binding Mode Assessment of N‑[4-[2-Propyn-1-yl[(6S)‑4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo‑3H‑cyclopenta[g]quinazolin-6-yl]amino]benzoyl]‑l‑γ-glutamyl‑d‑glutamic Acid (BGC 945), a Novel Thymidylate Synthase Inhibitor That Targets Tumor Cells
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T18%3A37%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20and%20Binding%20Mode%20Assessment%20of%20N%E2%80%91%5B4-%5B2-Propyn-1-yl%5B(6S)%E2%80%914,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo%E2%80%913H%E2%80%91cyclopenta%5Bg%5Dquinazolin-6-yl%5Damino%5Dbenzoyl%5D%E2%80%91l%E2%80%91%CE%B3-glutamyl%E2%80%91d%E2%80%91glutamic%20Acid%20(BGC%20945),%20a%20Novel%20Thymidylate%20Synthase%20Inhibitor%20That%20Targets%20Tumor%20Cells&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Tochowicz,%20Anna&rft.date=2013-07-11&rft.volume=56&rft.issue=13&rft.spage=5446&rft.epage=5455&rft.pages=5446-5455&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/jm400490e&rft_dat=%3Cproquest_pubme%3E1490716465%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a405t-ba70a21b924b3eab6f9ef5ff2973851f1e654a55287cb2319ff5ee0ffb97ed7b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1490716465&rft_id=info:pmid/23710599&rfr_iscdi=true